These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23559388)

  • 1. Adalimumab-associated antiphospholipid syndrome: a case report and review of the literature.
    Hemmati I; Kur J
    Clin Rheumatol; 2013 Jul; 32(7):1095-8. PubMed ID: 23559388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.
    Ramos-Casals M; Brito-Zerón P; Muñoz S; Soria N; Galiana D; Bertolaccini L; Cuadrado MJ; Khamashta MA
    Medicine (Baltimore); 2007 Jul; 86(4):242-251. PubMed ID: 17632266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab.
    Korsten P; Sweiss NJ; Nagorsnik U; Niewold TB; Gröne HJ; Gross O; Müller GA
    Am J Kidney Dis; 2010 Dec; 56(6):e17-21. PubMed ID: 20974510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.
    Armuzzi A; Lionetti P; Blandizzi C; Caporali R; Chimenti S; Cimino L; Gionchetti P; Girolomoni G; Lapadula G; Marchesoni A; Marcellusi A; Mennini FS; Salvarani C; Cimaz R
    Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):11-32. PubMed ID: 24774504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab in the treatment of immune-mediated diseases.
    Lapadula G; Marchesoni A; Armuzzi A; Blandizzi C; Caporali R; Chimenti S; Cimaz R; Cimino L; Gionchetti P; Girolomoni G; Lionetti P; Marcellusi A; Mennini FS; Salvarani C
    Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):33-48. PubMed ID: 24774505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psoriasiform dermatitis in a non-psoriatic patient treated with adalimumab.
    Tammaro A; Persechino S; Abruzzese C; Narcisi A; Cortesi G; Parisella FR; Laganà B
    Int J Immunopathol Pharmacol; 2012; 25(2):499-501. PubMed ID: 22697082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
    Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
    Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.
    Neri P; Zucchi M; Allegri P; Lettieri M; Mariotti C; Giovannini A
    Int Ophthalmol; 2011 Apr; 31(2):165-73. PubMed ID: 21287227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
    Poddubnyy D; Rudwaleit M
    Expert Opin Drug Saf; 2011 Jul; 10(4):655-73. PubMed ID: 21554150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Squamous cell carcinoma of the lip associated with adalimumab therapy for ankylosing spondylitis: a case report and review of TNF-α inhibitors and cutaneous carcinoma risk.
    Zitelli KB; Zedek D; Ranganathan P; Amerson EH
    Cutis; 2013 Jul; 92(1):35-9. PubMed ID: 23961524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases.
    Wiedmann MW; Mössner J; Baerwald C; Pierer M
    Endocr Metab Immune Disord Drug Targets; 2009 Sep; 9(3):295-314. PubMed ID: 19594416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France.
    Saint Marcoux B; De Bandt M;
    Joint Bone Spine; 2006 Dec; 73(6):710-3. PubMed ID: 17127088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab for the treatment of ankylosing spondylitis.
    Sieper J; Rudwaleit M; Braun J
    Expert Opin Pharmacother; 2007 Apr; 8(6):831-8. PubMed ID: 17425478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
    Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
    Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-label dermatologic uses of anti-TNF-a therapies.
    Alexis AF; Strober BE
    J Cutan Med Surg; 2005 Dec; 9(6):296-302. PubMed ID: 16699906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BH1 idiotype defines a population of anticardiolipin antibodies closely associated with the antiphospholipid syndrome.
    Mason AN; Harmer IJ; Mageed RA; Mackworth-Young CG
    Lupus; 1999; 8(3):234-9. PubMed ID: 10342717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.